Evidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patients

被引：35
|
作者：
Margiotti, K
Sangiuolo, F
De Luca, A
Froio, F
Pearce, CL
Ricci-Barbini, V
Micali, F
Bonafè, M
Franceschi, C
Dallapiccola, B
Novelli, G
Reichardt, JKV
机构：
[1] Univ Roma Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, I-00133 Rome, Italy
[2] USC, Keck Sch Med, Dept Biochem & Mol Biol, Inst Med Genet, Los Angeles, CA USA
[3] Osped Villa San Pietro, Serv Patol Clin, Rome, Italy
[4] USC, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA USA
[5] Osped CSS, IRCCS, Div Urol, San Giovanni Rotondo, Italy
[6] Univ Bologna, Dipartimento Patol Sperimentale, I-40126 Bologna, Italy
[7] Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Rome, Italy
[8] CSS Mendel Inst, Rome, Italy
来源：
DISEASE MARKERS | 2000年 / 16卷 / 3-4期
关键词：
prostate cancer; SRD5A2; gene; prostate cancer risk; polymorphic variant;
D O I：
10.1155/2000/683607
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
We have investigated the contributions of three polymorphic markers in the SRD5A2 gene to prostate cancer in a group of Italian patients. We have genotyped cases and controls for a polymorphic (TA), dinucleotide repeat and two functional substitutions, A49T and V89L, substituting respectively alanine with threonine at codon 49, and valine to leucine at codon 89, We found a substantially increased but not significant risk associated with the 49T mutation and a reduction of risk for the V89L substitution. In conclusion, we report on preliminary evidence for both increased and decreased risk associated with separate markers at this locus.
引用
收藏
页码：147 / 150
页数：4
相关论文
共 50 条
  • [41] The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men
    Allen, NE
    Forrest, MS
    Key, TJ
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (03) : 185 - 189
  • [42] Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis
    Li, Qiaoxin
    Zhu, Yao
    He, Jing
    Wang, Mengyun
    Zhu, Meiling
    Shi, Tingyan
    Qiu, Lixin
    Ye, Dingwei
    Wei, Qingyi
    [J]. MOLECULAR BIOLOGY REPORTS, 2013, 40 (05) : 3597 - 3608
  • [43] Sex dependent influence of a functional polymorphism in steroid 5--reductase type 2 (SRD5A2) on post-traumatic stress symptoms
    Gillespie, Charles F.
    Almli, Lynn M.
    Smith, Alicia K.
    Bradley, Bekh
    Kerley, Kimberly
    Crain, Daniel F.
    Mercer, Kristina B.
    Weiss, Tamara
    Phifer, Justine
    Tang, Yilang
    Cubells, Joseph F.
    Binder, Elisabeth B.
    Conneely, Karen N.
    Ressler, Kerry J.
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2013, 162B (03) : 283 - 292
  • [44] In vitro functional study of fifteen SRD5A2 variants found in Chinese patients and the relation between the SRD5A2 genotypes and phenotypes
    Zhang, Wei
    Yu, Bingging
    Luo, Wei
    Sun, Bang
    Zhang, Xiaoxia
    Wang, Xi
    Mao, Jiangfeng
    Nie, Min
    Wu, Xueyan
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2023, 235
  • [45] Differential and cell type-dependent transcriptional regulation of SRD5A1, SRD5A2, and SRD5A3 in the androgen receptor pathway in prostate cancer
    Li, Jin
    Mills, Gordon
    Huang, Miao
    Lin, Sue-Hwa
    Logothetis, Christopher
    Kim, Jeri
    [J]. CANCER RESEARCH, 2009, 69
  • [46] Association between SRD5A2 polymorphism and hypospadias: a meta-analysis
    Sun, Liquan
    Zhou, Mei
    Liu, Tao
    [J]. PHARMAZIE, 2019, 74 (02): : 125 - 128
  • [47] No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned
    Pearce, C. Leigh
    Van Den Berg, David J.
    Makridakis, Nick
    Reichardt, Juergen K. V.
    Ross, Ronald K.
    Pike, Malcolm C.
    Kolonel, Laurence N.
    Henderson, Brian E.
    [J]. HUMAN MOLECULAR GENETICS, 2008, 17 (16) : 2456 - 2461
  • [48] KLK3 AND STEROID 5-ALPHA REDUCTASE TYPE II (SRD5A2) GENE POLYMORPHISMS MIGHT AFFECT CLINICAL RELIABILITY OF SERUM PSA MEASUREMENT
    Zambon, C. -F.
    Padoan, A.
    Prayer-Galetti, T.
    Basso, D.
    Moz, S.
    Secco, S.
    Pelloso, M.
    Greco, E.
    Fogar, P.
    Navaglia, F.
    Bozzato, D.
    Fadi, E.
    Zattoni, F.
    Plebani, M.
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S281 - S281
  • [49] Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population
    Li, ZH
    Habuchi, T
    Mitsumori, K
    Kamoto, T
    Kinoshitu, H
    Segawa, T
    Ogawa, O
    Kato, T
    [J]. JOURNAL OF UROLOGY, 2003, 169 (06): : 2378 - 2381
  • [50] The Association of SRD5A2 Gene Polymorphism at Codon 89 and Prostate Cancer Risk: Case Control Study
    Dusenka, R.
    Tomaskin, R.
    Grobarcikova, S.
    Sivonova, Kmetova M.
    Dobrota, D.
    Kliment, J.
    [J]. UROLOGY, 2012, 80 (03) : S82 - S83
12345